[Severe hemorrhagic complications during treatment with low molecular weight heparin. Apropos of 2 cases].
Two cases of fatal bleeding in patients treated with low molecular weight heparin for deep vein thrombosis are reported. Risk factors for bleeding were: severe underlying disease (cancer in one case, morbid obesity and cardiac failure in the other), age over 80 years and worsening of renal insufficiency in both cases, recent surgical procedure in one case. Anti-Xa activity was beyond the therapeutic range at the time of bleeding in both cases. The usefulness of biologically monitoring the treatment of deep vein thrombosis with low molecular weight heparin is discussed.
Grateau
G
G
Service de médecine interne, Hôtel-Dieu, Paris, France.
Chauvenet
L
L
Oudard
S
S
Bachmeyer
C
C
Capron
L
L
Horellou
M H
MH
Samama
M M
MM
D000368:Aged; D000369:Aged, 80 and over; D065427:Factor Xa Inhibitors; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006470:Hemorrhage / Q000097:blood / Q000139:chemically induced*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D012307:Risk Factors; D013924:Thrombophlebitis / Q000188:drug therapy
D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight